Categories: Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk, Deals & Cases
Share:
31 January 2020 
Resistell AG has closed a milestone-based CHF 3.5M Series A Financing round led by OCCIDENT. TRUMPF Venture, Alpana Ventures, Zürcher Kantonalbank, HEMEX and seven private investors also back the start-up developing world’s fastest phenotypic antibiotic susceptibility test. VISCHER AG (Matthias Staehelin and Livia Pedrojetta, both Corporate) is advising Resistell AG.
Matthias Staehelin
Attorney at Law and Civil Law Notary (BS/BL)
- Partner
- +41 58 211 33 53
- [email protected]